Literature DB >> 35000018

Role of proliferative marker index and KBTBD4 mutation in the pathological diagnosis of pineal parenchymal tumors.

Eita Uchida1,2, Atsushi Sasaki3, Mitsuaki Shirahata4, Tomonari Suzuki4, Jun-Ichi Adachi4, Kazuhiko Mishima4, Masanori Yasuda5, Takamitsu Fujimaki6, Koichi Ichimura7,8, Ryo Nishikawa4.   

Abstract

Pineal parenchymal tumors (PPTs) are clinically rare and a biopsy is often required for a definitive diagnosis. To improve the accuracy of histological assessment of PPTs, we examined the proliferative capacity of PPT cells and investigated DICER1 expression and KBTBD4 mutations. This study included 19 cases of PPTs [3 pineocytomas (PCs), 10 PPTs of intermediate differentiation (PPTID), and 6 pineoblastomas (PBs)]. Immunohistochemistry for Ki-67, PHH3, and DICER1, as well as Sanger sequencing analysis for KBTBD4 mutations, was performed using formalin-fixed paraffin-embedded tissue specimens that were resected during surgery. Tumor cell proliferation was quantified using an image analysis software. For the PHH3 and MIB-1 indices, a significant difference was observed between the PPTIDs and PBs (P < 0.05). Loss of DICER1 was not specific for PB; 0/3 PCs (0.0%), 2/9 PPTIDs (22.2%), and 2/4 PBs (50.0%). KBTBD4 mutations were detected in 1/3 PCs (33.3%), 6/9 PPTIDs (66.7%), and 0/4 PBs (0.0%). Thus, combined application of the proliferative marker index and KBTBD4 mutation analysis may be useful for the differential diagnosis of PPTs. Furthermore, detection of KBTBD4 mutations using Sanger sequencing analysis may support the diagnosis of PPTID.
© 2021. The Author(s) under exclusive licence to The Japan Society of Brain Tumor Pathology.

Entities:  

Keywords:  Differential diagnosis; KBTBD4 mutation; MIB-1; PHH3; Pineal parenchymal tumor

Mesh:

Substances:

Year:  2022        PMID: 35000018     DOI: 10.1007/s10014-021-00421-2

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  31 in total

1.  Parenchymal pineal tumors: a clinicopathological study of 76 cases.

Authors:  F Fauchon; A Jouvet; P Paquis; G Saint-Pierre; C Mottolese; M Ben Hassel; L Chauveinc; J P Sichez; J Philippon; M Schlienger; E Bouffet
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-03-01       Impact factor: 7.038

2.  Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma.

Authors:  Susan N Chi; Sharon L Gardner; Adam S Levy; Edmond A Knopp; Douglas C Miller; Jeffrey H Wisoff; Howard L Weiner; Jonathan L Finlay
Journal:  J Clin Oncol       Date:  2004-12-15       Impact factor: 44.544

3.  Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds.

Authors:  Eleonora Duregon; Adele Cassenti; Alessandra Pittaro; Laura Ventura; Rebecca Senetta; Roberta Rudà; Paola Cassoni
Journal:  Neuro Oncol       Date:  2015-02-01       Impact factor: 12.300

4.  Extent of Resection and Long-Term Survival of Pineal Region Tumors in Helsinki Neurosurgery.

Authors:  Joham Choque-Velasquez; Julio Resendiz-Nieves; Behnam Rezai Jahromi; Roberto Colasanti; Rahul Raj; Juho Vehviläinen; Olli Tynninen; Juhani Collan; Mika Niemelä; Juha Hernesniemi
Journal:  World Neurosurg       Date:  2019-07-30       Impact factor: 2.104

5.  Germ-line and somatic DICER1 mutations in pineoblastoma.

Authors:  Leanne de Kock; Nelly Sabbaghian; Harriet Druker; Evan Weber; Nancy Hamel; Suzanne Miller; Catherine S Choong; Nicholas G Gottardo; Ursula R Kees; Surya P Rednam; Liselotte P van Hest; Marjolijn C Jongmans; Shalini Jhangiani; James R Lupski; Margaret Zacharin; Dorothée Bouron-Dal Soglio; Annie Huang; John R Priest; Arie Perry; Sabine Mueller; Steffen Albrecht; David Malkin; Richard G Grundy; William D Foulkes
Journal:  Acta Neuropathol       Date:  2014-07-15       Impact factor: 17.088

6.  Pineoblastoma is uniquely tolerant of mutually exclusive loss of DICER1, DROSHA or DGCR8.

Authors:  Leanne de Kock; Barbara Rivera; William D Foulkes
Journal:  Acta Neuropathol       Date:  2020-03-02       Impact factor: 17.088

7.  Utility of Ki67 immunostaining in the grading of pineal parenchymal tumours: a multicentre study.

Authors:  M Fèvre-Montange; A Vasiljevic; D Frappaz; J Champier; A Szathmari; M-H Aubriot Lorton; F Chapon; A Coulon; I Quintin Roué; M-B Delisle; D Figarella-Branger; A Laquerrière; C Miquel; J-F Michiels; M Péoch; M Polivka; F Fauchon; A Jouvet
Journal:  Neuropathol Appl Neurobiol       Date:  2012-02       Impact factor: 8.090

8.  Treatment of young children with CNS-primitive neuroectodermal tumors/pineoblastomas in the prospective multicenter trial HIT 2000 using different chemotherapy regimens and radiotherapy.

Authors:  Carsten Friedrich; André O von Bueren; Katja von Hoff; Nicolas U Gerber; Holger Ottensmeier; Frank Deinlein; Martin Benesch; Robert Kwiecien; Torsten Pietsch; Monika Warmuth-Metz; Andreas Faldum; Joachim Kuehl; Rolf D Kortmann; Stefan Rutkowski
Journal:  Neuro Oncol       Date:  2012-12-07       Impact factor: 12.300

9.  Long-term evidence that a pediatric oncology mentorship program for young investigators is feasible and beneficial in the cooperative group setting: A report from the Children's Oncology Group.

Authors:  Adam J Esbenshade; Christopher R Pierson; Amanda L Thompson; Damon Reed; Abha Gupta; Adam Levy; Lisa S Kahalley; Paul Harker-Murray; Reuven Schore; Jodi A Muscal; Leanne Embry; Kelly Maloney; Terzah Horton; Patrick Zweidler-Mckay; Girish Dhall
Journal:  Pediatr Blood Cancer       Date:  2017-11-28       Impact factor: 3.167

10.  Structural basis for Cul3 protein assembly with the BTB-Kelch family of E3 ubiquitin ligases.

Authors:  Peter Canning; Christopher D O Cooper; Tobias Krojer; James W Murray; Ashley C W Pike; Apirat Chaikuad; Tracy Keates; Chancievan Thangaratnarajah; Viktorija Hojzan; Vikram Ayinampudi; Brian D Marsden; Opher Gileadi; Stefan Knapp; Frank von Delft; Alex N Bullock
Journal:  J Biol Chem       Date:  2013-01-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.